Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Editas Medicine, Inc. - Common Stock (NQ: EDIT )

1.370 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Editas Medicine, Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Benzinga's Top Ratings Upgrades, Downgrades For November 18, 2022
Upgrades 
Via Benzinga
Palo Alto To Surge Around 38%? Plus This Analyst Predicts $65 For Helmerich & Payne
Barclays raised the price target on Palo Alto Networks, Inc. (NASDAQ: PANW) from $200 to $215. Barclays analyst Saket Kalia maintained an Overweight rating on the stock. Palo Alto Networks shares fell... 
Via Benzinga
Intuit To $490? Here Are 5 Other Price Target Changes For Friday
Barclays cut Intuit Inc. (NASDAQ: INTU) price target from $502 to $490. . Barclays analyst Raimo Lenschow maintained an Overweight rating on the stock. Intuit shares fell 3% to close at $381.88 on... 
Via Benzinga
Why Editas Medicine's Shares Are Falling Thursday
The company shelved a clinical trial for one of its lead therapies. 
Via The Motley Fool
Editas Medicine: Q3 Earnings Insights
Editas Medicine (NASDAQ:EDIT) reported its Q3 earnings results on Wednesday, November 2, 2022 at 06:30 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Editas Medicine's Return On Capital Employed Insights
  
Via Benzinga
Gap To Rally 18%? Plus This Analyst Slashes PT On Super League Gaming By 50%
  Telsey Advisory Group boosted the price target on The Gap, Inc. (NYSE: GPS) from $10 to $15. Gap shares rose 5.6% to close at $12.71 on Thursday. 
Via Benzinga
Why Inotiv Shares Dipped 57%; Here Are 76 Biggest Movers From Yesterday
Gainers Satixfy Communications Ltd. (NYSE: SATX) jumped 96.4% to settle at $51.70 on Thursday. 
Via Benzinga
Editas Medicine: Q2 Earnings Insights
  Editas Medicine (NASDAQ:EDIT) reported its Q2 earnings results on Wednesday, August 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
BMO Initiates Coverage On This Gene Editing Spearhead
Via Benzinga
Nasdaq Down 60 Points; Alibaba Posts Upbeat Q2 Earnings
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite dropping around 60 points on Thursday. 
Via Benzinga
Why Elevate Credit Shares Are Trading Higher By Over 71%? Here Are 43 Stocks Moving In Thursday's Mid-Day Session
Gainers Elevate Credit, Inc. (NYSE: ELVT) shares surged 71.2% to $1.8150 after the company agreed to be acquired by Park Cities Asset Management in an all-cash transaction at an implied value of $67... 
Via Benzinga
Citing Small Population, Editas Medicine Pauses Work On Gene Therapy Trial For Genetic Eye Disorder
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
S&P 500 Down 1%; Crude Oil Drops Sharply
U.S. stocks traded lower midway through trading, with the S&P 500 dropping around 1% on Thursday. 
Via Benzinga
BrightView Holdings, America's Car-Mart And Some Other Big Stocks Moving Lower On Thursday
U.S. stocks traded lower, with the Nasdaq dropping more than 100 points on Thursday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Editas Medicine Announces Clinical Data Demonstrating Proof of Concept of EDIT-101 from Phase 1/2 BRILLIANCE Trial
From Editas Medicine, Inc.
Via GlobeNewswire
What 5 Analyst Ratings Have To Say About Editas Medicine
Over the past 3 months, 5 analysts have published their opinion on Editas Medicine (NASDAQ:EDIT) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
Editas Medicine Announces Third Quarter 2022 Results and Business Updates
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine to Host Conference Call Discussing Third Quarter 2022 Results and Corporate Update
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine Presents Preclinical Data on EDIT-103 for Rhodopsin-associated Autosomal Dominant Retinitis Pigmentosa at the European Society of Gene and Cell Therapy Annual Meeting
From Editas Medicine, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For September 29, 2022
Upgrades 
Via Benzinga
Intellia Therapeutics Looks To Repeat Its Landmark Success In CRISPR Gene Editing
Intellia tested its CRISPR approach in cardiomyopathy and hereditary angioedema. 
Via Investor's Business Daily
3 Biotech Stocks Gaining Momentum
The headlines have been particularly good for a trio of small cap biotechs and it appears the momentum may have staying power. 
Via MarketBeat
Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Editas Medicine Announces Clinical Achievements in the Development of EDIT-301 for Sickle Cell Disease
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine to Host Conference Call Discussing Second Quarter 2022 Results and Corporate Updates
From Editas Medicine, Inc.
Via GlobeNewswire
The 3 Leaders of the Gene Editing Revolution
There's a wide field of gene editing stocks, but if you're looking for the best opportunities, there are a few likely winners to watch. 
Via InvestorPlace
7 Moonshot Investments Upending a $10 Trillion Industry
Gene editing is expensive at an estimated $5 billion per drug, but it could change the world in the very near future. 
Via InvestorPlace
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.